Krystal Biotech, Inc. (NASDAQ:KRYS) Holdings Raised by Perigon Wealth Management LLC

Perigon Wealth Management LLC increased its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 1.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,289 shares of the company’s stock after purchasing an additional 123 shares during the quarter. Perigon Wealth Management LLC’s holdings in Krystal Biotech were worth $1,200,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB acquired a new stake in shares of Krystal Biotech during the third quarter worth $40,000. Values First Advisors Inc. acquired a new stake in Krystal Biotech during the third quarter worth about $53,000. GAMMA Investing LLC lifted its holdings in Krystal Biotech by 184.8% in the third quarter. GAMMA Investing LLC now owns 430 shares of the company’s stock worth $78,000 after acquiring an additional 279 shares during the last quarter. Huntington National Bank boosted its stake in Krystal Biotech by 97.6% in the third quarter. Huntington National Bank now owns 573 shares of the company’s stock valued at $104,000 after acquiring an additional 283 shares during the period. Finally, Blue Trust Inc. grew its holdings in shares of Krystal Biotech by 242.4% during the third quarter. Blue Trust Inc. now owns 582 shares of the company’s stock valued at $107,000 after purchasing an additional 412 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the sale, the insider now owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 14.10% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a report on Wednesday, December 18th. Citigroup boosted their price target on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $212.00 price objective on shares of Krystal Biotech in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $206.67.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock opened at $156.07 on Friday. Krystal Biotech, Inc. has a 1-year low of $107.50 and a 1-year high of $219.34. The company has a market capitalization of $4.49 billion, a P/E ratio of 88.18 and a beta of 0.85. The business’s fifty day moving average price is $166.79 and its two-hundred day moving average price is $180.18.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.07. The business had revenue of $83.84 million for the quarter, compared to analysts’ expectations of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company’s revenue was up 879.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.67) earnings per share. On average, research analysts expect that Krystal Biotech, Inc. will post 3.03 earnings per share for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).